Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma [0.03%]
尼妥珠单抗联合吉西他滨和顺铂治疗复发非小细胞肺癌临床研究
Fumihiko Kinoshita,Yuka Oku,Shinkichi Takamori et al.
Fumihiko Kinoshita et al.
Background: The efficacy and safety of the anti-EGFR antibody necitumumab combined with gemcitabine and cisplatin (N + GC) in the first-line treatment of advanced lung squamous cell carcinoma (LSCC) have been proven. Howe...
TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells' killing [0.03%]
TRIM59保护内质网蛋白稳态并防止硼替佐米介导的结直肠癌细胞凋亡
Xuejia Feng,Gui Yang,Litian Zhang et al.
Xuejia Feng et al.
The endoplasmic reticulum (ER) is a critical organelle that preserves the protein homeostasis of cells. Under various stress conditions, cells evolve a degree of capacity to maintain ER proteostasis, which is usually augmented in tumor cell...
Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia [0.03%]
四砷四硫化物能增强对全反式维甲酸耐药的急性早幼粒细胞白血病的NK-92MI介导的细胞免疫治疗
Yanfeng Liu,Yan Jia,Yi Liu et al.
Yanfeng Liu et al.
Acute promyelocytic leukemia (APL) is liable to induce disseminated intravascular coagulation and has a high early mortality. Although the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has significantly improved t...
Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer [0.03%]
纳武利尤单抗联合伊匹木单抗治疗肺癌时的整体肿瘤负荷与严重免疫相关不良事件的关系
Toshiyuki Sumi,Motoki Sekikawa,Yuta Nagahisa et al.
Toshiyuki Sumi et al.
Compared to chemotherapy alone, monoclonal antibodies like ipilimumab and nivolumab, with or without chemotherapy, improve the prognosis of patients with non-small cell lung cancer (NSCLC), albeit with a higher incidence of immune-related a...
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161 [0.03%]
一项评价sapanisertib（TAK-228）(mTORC1/2抑制剂)在雷帕霉素类似物耐药的晚期胰腺神经内分泌肿瘤疗效的II期研究（EA2161）
Lakshmi Rajdev,Ju-Whei Lee,Steven K Libutti et al.
Lakshmi Rajdev et al.
This was a two-stage phase II trial of a mTORC1/2 inhibitor (mTORC: mammalian target of rapamycin complex) Sapanisertib (TAK228) in patients with rapalog-resistant pancreatic neuroendocrine tumors (PNETs) (NCT02893930). Approved rapalogs su...
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer [0.03%]
帕博利珠单抗单药或联合化疗一线治疗非小细胞肺癌后发生严重免疫相关不良事件的风险因素分析
Toshiyuki Sumi,Yuta Koshshino,Motoki Sekikawa et al.
Toshiyuki Sumi et al.
Pembrolizumab treatment is associated with a favorable prognosis in patients with non-small-cell lung cancer (NSCLC). Here, we investigated the associations among pre-treatment clinical factors, baseline overall tumor burden, and developmen...
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab [0.03%]
阿特朱单抗与贝伐珠单抗治疗不可切除肝细胞癌患者甲胎蛋白反应的最适阈值分析
Nobuharu Tamaki,Toshifumi Tada,Masayuki Kurosaki et al.
Nobuharu Tamaki et al.
Alpha-fetoprotein (AFP) response (relative decline in AFP) is associated with imaging response evaluated by response evaluation criteria in solid tumors ver1.1 (RECIST) and survival in treatment for hepatocellular carcinoma (HCC). However, ...
Multicenter Study
Investigational new drugs. 2022 Dec;40(6):1290-1297. DOI:10.1007/s10637-022-01303-w 2022
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy [0.03%]
奥希替尼失败后T790M阴性患者的再次取活检和TKI治疗
Shinsuke Ogusu,Ryo Ariyasu,Takahiro Akita et al.
Shinsuke Ogusu et al.
Data on the re-administration of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) after osimertinib failure in patients with T790M-positive non-small cell lung cancer (NSCLC) is limited. EGFR-TKI re-administration e...
Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations [0.03%]
罕见和常见EGFR突变共存的腺癌患者的长期疗效观察
Shinichiro Okauchi,Hiroaki Satoh
Shinichiro Okauchi
Recently, we read a paper "Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation" published in Investigational New Drugs. Their patient had a very rare ...
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer [0.03%]
CYP3A4/5和ABC转运体多态性对日本非小细胞肺癌患者奥希替尼血药浓度的影响
Hayato Yokota,Kazuhiro Sato,Sho Sakamoto et al.
Hayato Yokota et al.
The effects of polymorphisms in CYP3A4 (20230G > A), CYP3A5 (6986A > G), ABCB1 (1236C > T, 2677G > T/A, 3435C > T), ABCG2 (421C > A), and ABCC2 (-24C > T) on the area under the concentration-time curve (AUC) of osimertinib in 23 patients wi...